The Importance of Identification of M-BCRABL Oncogene and JAK2^V617F Mutation in Myeloproliferative Neoplasms

1. Tefferi A, Thiele J, Vardiman J. The 2008 World Health Organization Classifi cation System for Myeloproliferative Neoplasms-order out of Chaos. Cancer. 2009:3842-3847.10.1002/cncr.24440Search in Google Scholar

2. Vardiman J, Thiele J, Daniel A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.10.1182/blood-2009-03-209262Search in Google Scholar

3. Koopmans SM, van Marion AMW, Schouten HC. Myeloproliferative neoplasia: a review of clinical criteria and treatment. Neth J Med. 2012;70(4):159-165.Search in Google Scholar

4. Pane F, Intrieri M, Quintarelli C, et al. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene. 2002;21(56):8652-8667.10.1038/sj.onc.1206094Search in Google Scholar

5. McLornan D, Percy M, McMullin M. JAK2V617F: A Single Mutation in the Myeloproliferative Group of Disorders. Ulster Med J. 2006;75(2):112-119.Search in Google Scholar

6. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357.10.1038/sj.leu.2403135Search in Google Scholar

7. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. Leukemia. 2003;17(12):2474-2486.10.1038/sj.leu.2403136Search in Google Scholar

8. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.10.1016/S0140-6736(05)71142-9Search in Google Scholar

9. Hehlmann R, Grimwade D, Simonsson B, et al. The European LeukemiaNet: achievements and perspectives. Haematologica. 2011;96(1):156-162.10.3324/haematol.2010.032979301278021048032Search in Google Scholar

10. Szántó A, Pap Z, Benedek I, et al. Monitoring M-BCR-ABL expression level in CML patients by RQ-PCR: experience of a single Center. Rom J Morphol Embryol. 2013;54(1):37-42.Search in Google Scholar

11. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.10.1200/JCO.2009.25.0779497910019884523Search in Google Scholar

12. Tefferi A, Vardiman JW. Classifi cation and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14-22.10.1038/sj.leu.240495517882280Search in Google Scholar

13. Schnittger S, Bacher U, Eder Ch, et al. Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workfl ow. Haematologica. 2012;97(10):1582-1585.10.3324/haematol.2012.064683348756022511494Search in Google Scholar

14. Scott ML, Tong W, Ross LL, et al. JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. N Engl J Med. 2007;356(5):459-468.10.1056/NEJMoa065202287383417267906Search in Google Scholar

15. Bojko P, Abenhardt W, Schnittger S, Haferlach T. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease. Onkologie. 2009;32(4):191-195.Search in Google Scholar

16. Cho YU, Chi HS, Lee EH, et al. Comparison of clinicopathologic fi ndings according to JAK2 V617F mutation in patients with essential thrombocythemia. Int J Hematol. 2009;89(1):39-44.10.1007/s12185-008-0222-019093167Search in Google Scholar

17. Ha JS, Kim YK, Jung SI, Jung HR, Chung IS. Correlations between Janus Kinase 2 V617F Allele Burdens and Clinicohematologic Parameters in Myeloproliferative Neoplasms. Ann Lab Med. 2012;32:385-391.10.3343/alm.2012.32.6.385348693123130336Search in Google Scholar

18. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G_T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome- negative CML, and megakaryocytic leukemia. Blood. 2005;106(10): 3370-3373.10.1182/blood-2005-05-1800189506516037387Search in Google Scholar

19. Pich A, Riera L, Sismondi F, et al. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol. 2009;62(9):798-801.10.1136/jcp.2009.06590419734476Search in Google Scholar

20. Hussein K, Bock O, Theophile K, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia. 2008;22:1059-1062.10.1038/sj.leu.240499317972958Search in Google Scholar

21. Inami M, Inokuchi K, Okabe M, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia. 2007;21:1103-1104.10.1038/sj.leu.240459117301812Search in Google Scholar

22. Cappetta M, Perez V, Zubillaga MN, et al. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in fi ve patients with myeloproliferative neoplasm at diagnosis. Int J Lab Hematol. 2013;35:e4- e5. 10.1111/ijlh.1201023062104Search in Google Scholar